Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Tipo de documento
Intervalo de ano de publicação
1.
Acta Neuropathol ; 129(6): 895-907, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25869641

RESUMO

Alzheimer's disease (AD) is characterized by extracellular amyloid ß (Aß) deposition and intracellular tau aggregation. Many studies have indicated some association between these processes, but it remains unknown how the two pathologies are linked. In this study, we investigated whether expression of amyloid precursor protein (APP) influences extracellular seed-dependent intracellular tau accumulation in cultured cells. Treatment of tau-expressing SH-SY5Y cells with Aß fibrils did not induce intracellular tau aggregation. On the other hand, in cells expressing both tau and APP, treatment with tau fibrils or Sarkosyl-insoluble tau from AD brains induced intracellular tau aggregation. The seed-dependent intracellular tau aggregation was not induced by expression of APP lacking the extracellular domain. The amount of phosphorylated tau aggregates in cultured cells was dose dependently elevated in response to increased levels of APP on the cell membrane. Our results indicate that the extracellular region of APP is involved in uptake of tau fibrils into cells, raising the possibility that APP, but not Aß, influences cell-to-cell spreading of tau pathologies in AD by serving as a receptor of abnormal tau aggregates.


Assuntos
Peptídeos beta-Amiloides/farmacologia , Precursor de Proteína beta-Amiloide/metabolismo , Citoplasma/metabolismo , Líquido Extracelular/metabolismo , Proteínas tau/metabolismo , Precursor de Proteína beta-Amiloide/genética , Animais , Linhagem Celular Tumoral , Citoplasma/ultraestrutura , Relação Dose-Resposta a Droga , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação da Expressão Gênica/genética , Humanos , Microscopia Confocal , Microscopia Imunoeletrônica , Mutação/genética , Neuroblastoma/patologia , Transfecção , Proteínas tau/farmacologia
2.
Biol Pharm Bull ; 35(7): 1105-17, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22791159

RESUMO

Treatment of PC12 cells with fungus-derived alkaloid neoechinulin A for more than 12 h renders the cells resistant to subsequent superoxide (O2⁻)/nitric oxide (NO) insults derived from 3-morpholinosydnonimine (SIN-1). However, the underlying mechanism(s) remains largely unclear. To elucidate the mechanism(s), we assessed the specificity of the cytoprotection afforded by neoechinulin A treatment using other cytocidal stressors and also clarified the resulting cellular alterations, focusing on the antioxidant and metabolic enzymes systems. Neoechinulin A treatment for more than 12 h endowed PC12 cells with significant resistance to transient NO toxicity, but not persistent NO toxicity, bolus H2O2 toxicity, or oxidative insult from the redox cycling quinone menadione. Cellular antioxidant system profiling revealed no substantial potentiation of the activity of any antioxidant enzyme in lysate from the neoechinulin A-treated cells excluding glutathione (GSH) content, which was significantly decreased (>50%), resulting in a proportional compromise in the thiol-reducing activity of the intact cells. In addition, no differences were observed in the activity for any nicotinamide adenine dinucleotide (phosphate) reduced form (NAD(P)H)-generating enzyme, steady-state NAD(P)H/nicotinamide adenine dinucleotide (phosphate) oxidized form (NAD(P)⁺) ratios, or the levels of total NAD(P)H. Nevertheless, the neoechinulin A-treated intact cells exhibited increased NAD(P)H redox turnover when driven by extracellular tetrazolium. The structurally inactive analog preechinulin failed to protect cells against NO toxicity or induce these alterations, suggesting their link with the cytoprotective mechanism. These results suggest that neoechinulin A, despite disabling the GSH defense system, confers cytoprotection against nitrosative stresses by elevating the cellular reserve capacity for NAD(P)H generation, which could offset crippling of energy-supplying systems due to nitrosative stress.


Assuntos
Citoproteção/efeitos dos fármacos , Alcaloides Indólicos/farmacologia , Óxido Nítrico/toxicidade , Piperazinas/farmacologia , Animais , Sobrevivência Celular/efeitos dos fármacos , Citoproteção/fisiologia , Glutationa/metabolismo , Molsidomina/análogos & derivados , Molsidomina/farmacologia , Nitrocompostos/farmacologia , Oxirredução , Estresse Oxidativo/efeitos dos fármacos , Oxirredutases/metabolismo , Células PC12 , Ratos , ATPase Trocadora de Sódio-Potássio/antagonistas & inibidores , Transferases/metabolismo
3.
Acta Neuropathol Commun ; 1: 54, 2013 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-24252707

RESUMO

BACKGROUND: Intracytoplasmic inclusions composed of filamentous tau proteins are defining characteristics of neurodegenerative tauopathies, but it remains unclear why different tau isoforms accumulate in different diseases and how they induce abnormal filamentous structures and pathologies. Two tau isoform-specific antibodies, RD3 and RD4, are widely used for immunohistochemical and biochemical studies of tau species in diseased brains. RESULTS: Here, we show that extensive irreversible post-translational deamidation takes place at asparagine residue 279 (N279) in the RD4 epitope of tau in Alzheimer's disease (AD), but not corticobasal degeneration (CBD) or progressive supranuclear palsy (PSP), and this modification abrogates the immunoreactivity to RD4. An antiserum raised against deamidated RD4 peptide specifically recognized 4R tau isoforms, regardless of deamidation, and strongly stained tau in AD brain. We also found that mutant tau with N279D substitution showed reduced ability to bind to microtubules and to promote microtubule assembly. CONCLUSION: The biochemical and structural differences of tau in AD from that in 4R tauopathies found in this study may therefore have implications for prion-like propagation of tau.


Assuntos
Doença de Alzheimer/metabolismo , Anticorpos/imunologia , Encéfalo/metabolismo , Proteínas tau/imunologia , Proteínas tau/metabolismo , Anticorpos/genética , Asparagina , Humanos , Immunoblotting , Imuno-Histoquímica , Microtúbulos/metabolismo , Mutação , Isoformas de Proteínas/genética , Isoformas de Proteínas/imunologia , Processamento de Proteína Pós-Traducional , Proteínas Recombinantes/metabolismo , Paralisia Supranuclear Progressiva/metabolismo , Proteínas tau/química , Proteínas tau/genética
4.
Neurosci Lett ; 510(1): 48-52, 2012 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-22249117

RESUMO

Presence of cytoplasmic tau aggregates is a hallmark of brains in patients with tauopathies such as Alzheimer's disease. However, the mechanism underlying formation of these insoluble tau aggregates remains elusive. In this study, we investigated the impact of prolonged nitric oxide (NO) exposure on neuronal SH-SY5Y cells overexpressing human tau. Treatment with the NO donor DETA NONOate for up to 48h resulted in an increase in S-nitrosation of cellular proteins, inactivation of proteasome, and impairment of respiration. Western blot analysis of Triton X-soluble fractions of NO-treated cells revealed that persistent NO treatment increased heterogeneity in tau molecule size, as a result of dephosphorylation, and induced the formation of sodium dodecyl sulfate (SDS)-stable oligomeric tau aggregates, stabilized by disulfide bonds. Moreover, further NO treatment induced the formation of SDS-stable insoluble tau mega-aggregates that were composed of dephosphorylated full-length tau molecules and other proteins, and were stabilized through disulfide bonds. Evaluation of the role of these tau aggregates as potential seeds for tau fibrillization and elucidation of their formation mechanism in our model, could lead to better understanding of the pathogenesis of tauopathies.


Assuntos
Óxido Nítrico/farmacologia , Tauopatias/metabolismo , Proteínas tau/química , Proteínas tau/metabolismo , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Linhagem Celular , Humanos , Nitrosação/efeitos dos fármacos , Ligação Proteica/efeitos dos fármacos , Solubilidade/efeitos dos fármacos , Estresse Fisiológico/efeitos dos fármacos , Tauopatias/induzido quimicamente , Tauopatias/patologia , Proteínas tau/genética
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa